

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Mezes, et al.
SERIAL NUMBER: 10/044,564 EXAMINER: Not Yet Assigned
FILING DATE: January 11, 2002 ART UNIT: 1635
FOR: Proteins and Nucleic Acids Encoding Same

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of the first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

RECEIVED
DEC 11 2002
TECH CENTER 1600/2900


THIS PAGE BLANK (USPTO)

APPLICANTS: Mezes et al.
U.S.S.N.: 10/044,564

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 21402-240 (Cura-540).


Respectfully submitted,

 92,769
Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicant
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: December 6, 2002

TRA 1738984v1

THIS PAGE BLANK (USPTO)



Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/044,564
	Filing Date	01/11/02
	First Named Inventor	Mezes
	Group Art Unit	1635
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	21402-240 (Cura-540)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO	02/04480	Human Genome Sciences, Inc.	1/17/02		
	B2	WO	97/33995	Munin Corporation	9/18/97		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C237	International Search report for PCT/US 02/00609, mailed 11/15/02.
	C238	Kestila, et al. "Positionally Cloned Gene for a Novel Glomerular Protein-Nephrin-Is Mutated in Congenital Nephrotic Syndrome" <i>Molecular Cell</i> :575-582.
	C239	Wu, et al. (2000). "Characterization of differential gene expression in monkey arterial neointima following balloon catheter injury" <i>International Journal of Molecular Medicine</i> 6:433-440.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1738942v1

RECEIVED
DEC 11 2002
TECH CENTER 1600/2900

THIS PAGE BLANK (USPTO)